Pancoast tumor diagnostics present unique challenges because these rare lung cancers develop in a location where they often remain hidden until they cause pain and nerve-related symptoms rather than typical lung cancer signs.

Introduction: Who Needs Diagnostic Testing for Pancoast Tumors

People who experience persistent shoulder pain that does not improve with usual treatments should consider seeking medical evaluation that includes diagnostic testing for Pancoast tumors. This is especially important if the shoulder discomfort is accompanied by pain traveling down the arm, hand weakness, or unusual symptoms affecting one side of the face, such as a drooping eyelid or changes in sweating patterns.^[1]

Because Pancoast tumors grow at the very top of the lung, they rarely cause the breathing problems, persistent cough, or chest pain that people typically associate with lung cancer. Instead, the tumor presses against nearby nerves and bones, creating a distinctive pattern of discomfort that can easily be mistaken for orthopedic problems like rotator cuff injuries, cervical disc disease, or frozen shoulder. This misleading presentation often leads patients and their doctors down the wrong diagnostic path initially, which is why awareness of this possibility is so important.^[5]

Individuals with risk factors for lung cancer should be particularly vigilant about unusual, persistent pain in the shoulder region. These risk factors include a history of smoking, exposure to secondhand smoke over many years, long-term contact with substances like asbestos or radon gas, and occupational exposure to industrial materials such as gold or nickel. Even people who work in industries where shoulder injuries are common—such as those involving heavy lifting or repetitive arm movements—should not automatically assume their pain is work-related if it persists beyond what would be expected for a simple muscle strain.^[1]

Specific symptoms that should prompt immediate diagnostic evaluation include severe pain in the shoulder or shoulder blade that radiates down the arm following a specific path—typically along the inner side of the arm toward the hand, particularly affecting the area near the pinky finger. Additional warning signs include weakness in the arm and hand, loss of grip strength, numbness or tingling sensations in the hand, muscle wasting in the hand or arm, and a group of facial symptoms known as Horner’s syndrome, which includes a drooping eyelid, a smaller pupil in one eye, facial flushing on one side, and decreased sweating on that same side of the face.^[1]

Classic Diagnostic Methods for Identifying Pancoast Tumors

Diagnosing a Pancoast tumor requires a combination of imaging techniques because standard chest X-rays often fail to reveal these tumors clearly, especially in their early stages. The tumor’s location at the uppermost part of the lung, tucked behind the collarbone and first ribs, makes it difficult to visualize on traditional two-dimensional X-ray images. This diagnostic difficulty is one reason why there is frequently a delay between when symptoms first appear and when the correct diagnosis is made.^[1]

When a healthcare provider suspects a Pancoast tumor based on the patient’s symptoms and medical history, they typically order more sophisticated imaging studies. A computed tomography scan, commonly called a CT scan, is usually the next step after an initial chest X-ray. CT scans use multiple X-ray images taken from different angles and combine them with computer processing to create detailed cross-sectional images of the chest. This technology allows doctors to see the tumor’s exact location, its size, and critically important information about which surrounding structures it may have invaded, such as ribs, vertebrae, blood vessels, or nerve bundles.^[4]

Magnetic resonance imaging, or MRI, provides even more detailed pictures of soft tissues than CT scans. MRI uses powerful magnets and radio waves instead of radiation to create images. This technique is particularly valuable for evaluating Pancoast tumors because it can show with great precision whether the tumor has spread into the brachial plexus—the complex network of nerves that sends signals from the spinal cord to the shoulder, arm, and hand—or into the spinal column. Understanding the extent of nerve and spinal involvement is essential for determining whether the tumor can be surgically removed and planning the safest surgical approach if an operation is possible.^[4]

A positron emission tomography scan, known as a PET scan, is another imaging test that helps in diagnosing Pancoast tumors and determining if the cancer has spread. During a PET scan, a small amount of radioactive sugar is injected into the bloodstream. Cancer cells, which typically consume more sugar than normal cells, absorb larger amounts of this radioactive substance. A special camera then detects the radioactivity and creates images showing where the cancer is located. PET scans are particularly useful for identifying whether cancer has spread to lymph nodes in the chest or to distant parts of the body, which would change treatment recommendations.^[4]

While imaging tests can strongly suggest the presence of a Pancoast tumor, confirming the diagnosis requires obtaining a tissue sample through a procedure called a biopsy. There are several ways to perform a biopsy of a Pancoast tumor. A needle biopsy involves inserting a thin needle through the skin and into the tumor to remove a small piece of tissue. This procedure is typically guided by CT imaging to ensure the needle reaches the right location. The tissue sample is then examined under a microscope by a specialist called a pathologist, who can determine whether cancer cells are present and identify the specific type of cancer.^[1]

In some cases, doctors may recommend a biopsy performed through video-assisted thoracoscopic surgery, abbreviated as VATS. This minimally invasive surgical technique involves making small incisions in the chest wall and inserting a tiny camera along with surgical instruments. The surgeon can then visualize the tumor directly and remove a larger tissue sample for analysis. Another option is a biopsy through a small incision in the chest wall, sometimes called a small thoracotomy, which allows direct access to the tumor when other approaches are not suitable.^[4]

Endoscopic ultrasonography is another technique that may be used in the diagnostic process. This procedure combines endoscopy—using a flexible tube with a light and camera—with ultrasound imaging. The endoscope is passed down the throat and into the airways or esophagus, and sound waves create detailed images of nearby structures. This can help doctors better understand the tumor’s location and obtain tissue samples from nearby lymph nodes to check if the cancer has spread.^[8]

An important part of the diagnostic workup is determining the stage of the cancer, which describes how far it has spread. For Pancoast tumors, doctors particularly need to know whether the cancer has extended into the vertebrae (bones of the spine), invaded major blood vessels like the subclavian artery that supplies blood to the arms, or spread to lymph nodes in the middle of the chest called mediastinal lymph nodes. Invasion into certain structures or extensive lymph node involvement may mean that surgical removal is not possible.^[8]

Sometimes, additional procedures are needed to complete the staging evaluation. Mediastinoscopy is a surgical procedure in which a small incision is made at the base of the neck, and a thin tube is inserted into the chest to examine lymph nodes in the mediastinum and take samples. Bronchoscopy, which involves passing a flexible tube with a camera through the airways of the lungs, may also be performed to check whether the tumor has invaded the major breathing passages.^[8]

Diagnostic Testing for Clinical Trial Qualification

When patients with Pancoast tumors are being considered for enrollment in clinical trials, they typically undergo a comprehensive and standardized set of diagnostic tests. Clinical trials are research studies that test new treatments or new combinations of existing treatments. To ensure that study results are reliable and that participants are appropriate for the treatment being tested, trials have specific criteria, called inclusion and exclusion criteria, that determine who can participate.

The diagnostic workup for clinical trial enrollment generally begins with all the standard imaging studies described earlier: CT scans, MRI scans, and PET scans. These imaging tests must usually be performed within a specific timeframe before enrollment—often within four to six weeks—to ensure that the information about the tumor’s size and spread is current. Clinical trials often require very precise measurements of the tumor’s dimensions, which radiologists obtain from these scans.^[10]

A tissue biopsy confirming the diagnosis and identifying the specific type of lung cancer is always required for clinical trial participation. The tissue sample must be adequate not just for basic diagnosis but also for additional testing. Modern clinical trials increasingly require molecular testing of the tumor tissue, which means analyzing the cancer cells’ genetic material to look for specific mutations or proteins that might make the tumor responsive to particular targeted therapies. For example, researchers might test for mutations in genes called EGFR, ALK, ROS1, or KRAS, or look for the presence of certain proteins called PD-L1.^[12]

Blood tests are another standard component of the diagnostic process for clinical trial eligibility. These laboratory tests assess the function of major organs to ensure that patients are healthy enough to tolerate the treatment being studied. Common blood tests include a complete blood count to measure different types of blood cells, tests of kidney function such as creatinine and blood urea nitrogen, tests of liver function including measurements of liver enzymes and bilirubin, and sometimes assessments of blood sugar and cholesterol levels.

Patients being evaluated for clinical trials must also undergo careful assessment of their overall health status and functional capacity. Doctors use various scoring systems to rate how well patients can perform daily activities and how much the disease affects their lives. One commonly used system is the performance status scale, which rates patients from 0 (fully active, able to carry on all activities without restriction) to 4 (completely disabled, cannot carry out any self-care). Most clinical trials require patients to have a performance status of 0, 1, or 2, meaning they can take care of themselves even if they cannot work or do strenuous activities.^[10]

For patients with Pancoast tumors specifically, clinical trials often require additional specialized assessments. Because these tumors frequently invade the brachial plexus, trials may require detailed neurological examinations to document the extent of nerve damage. This baseline information is important for later determining whether the treatment being studied helps preserve or improve nerve function. Some trials may also require specialized nerve conduction studies or electromyography, which test how well nerves and muscles are working together.

Staging evaluations for clinical trials must be particularly thorough and follow standardized systems. The most commonly used staging system for lung cancer, including Pancoast tumors, is the TNM system. The T describes the size and extent of the primary tumor, N describes whether cancer has spread to nearby lymph nodes, and M indicates whether cancer has spread to distant parts of the body. Clinical trials typically specify exactly which stages of disease are eligible. For Pancoast tumors, many trials focus on stage III disease, where the tumor is locally advanced but has not spread to distant organs.^[10]

Some clinical trials require repeat imaging or biopsies at specific time points during and after treatment to assess how well the treatment is working. This means participants must be willing and able to undergo multiple diagnostic procedures. Researchers use these serial assessments to determine whether tumors are shrinking, remaining stable, or growing, and whether the cancer has spread to new locations. The imaging criteria for measuring tumor response in clinical trials follow standardized guidelines called RECIST criteria, which provide precise definitions of what constitutes tumor shrinkage, growth, or stability.

Before surgery is performed as part of a clinical trial protocol, patients typically undergo additional preoperative testing beyond what is needed for diagnosis alone. This includes thorough evaluation of heart and lung function to ensure patients can safely tolerate the operation. Pulmonary function tests measure how well the lungs are working and how much breathing capacity a patient would retain after part of a lung is removed. An electrocardiogram and sometimes an echocardiogram assess heart function and identify any cardiac problems that would increase surgical risk.^[10]

Documentation requirements for clinical trials are also more extensive than for standard care. Every test result must be carefully recorded, and source documents proving that tests were performed and results obtained must be maintained. This level of documentation ensures the integrity of the research and allows independent monitors to verify that the trial is being conducted properly and that all participants meet the eligibility criteria.